title: Central nervous system B-cell lymphoma in multiple sclerosis.
abstract: The differential diagnosis of multiple sclerosis is extensive and it can be     challenging to diagnose initially in the absence of pathognomonic clinical     features. Furthermore, these patients can also develop other diseases during     their course of treatment, which usually lasts for many years. Some conditions,     such as primary central nervous system lymphoma, can mimic clinically some of     the symptoms prominent in multiple sclerosis. Early treatment with     corticosteroids can also dramatically improve patient symptoms in both     conditions. We report a case of a man diagnosed with histologically confirmed     relapsing remitting multiple sclerosis who subsequently developed histologically     confirmed primary central nervous system lymphoma. The course of his disease and     treatment are presented and the current literature reviewed.
authors: Mayo Clinic Arizona, Department of Neurological Surgery, Phoenix/AZ, USA. lyons.mark2@mayo.edu
authors: Mark
authors: M
authors: Lyons
authors: Naresh
authors: N
authors: Patel
authors: Barry
authors: B
authors: Birch
authors: Orland
authors: O
authors: Boucher
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000150:complications*; D000068717:Glatiramer Acetate; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000150:complications*; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications*; D009460:Neurologic Examination; D010455:Peptides / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008775:Methylprednisolone